Adamis Pharmaceuticals Corp. (ADMP) Hits New 52-Week Low at $2.57
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $2.57 and last traded at $2.61, with a volume of 132,511 shares. The stock had previously closed at $2.61.
Separately, Maxim Group decreased their target price on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st.
The stock’s 50-day moving average price is $2.90 and its 200 day moving average price is $5.38. The company’s market cap is $40.33 million.
In related news, SVP David J. Marguglio sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $8.08, for a total value of $32,320.00. Following the sale, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.